15 may be a little much but I think a pop to 7 then to 10 until it bases. Going to be a long road but never less all the roads point upwards!!
This will prob pop to the upside a couple of points before it settles. Could hit the 9s but good luck if you are shorting.
Not to be funny, but this is up there with animal crulety and they should be jailed for misleading the public for personal wealth. Yahoo should remove SA do to ethical concerns. I do not even have shares of SRPT but have been following due to subject and cure
Updated data to be presented at the AACR also. Should keep ZIOP moving upward. You could feel the excitement and enthusiam in CEO Dr. Lewis presentation.
Will most likely be a very positive presentation. He mentioned on todays call that they are very excited about being in the pancreatic cancer arena. Monday should be very interesting $$$
They placed a Dreamteam in place to pump up the numbers by sales. This is to entice buyers so they can sell it. Business 101....................idiot.
Options for this story – GSK/Prosensa fails in Phase 3
Posted by John Campbell on September 21, 2013
Mindy Schneider Leffler
Options for this story
I am one of the families that has been devastated by today’s news in a personal way, as our son Aidan was participating in the phase III drisapersen extension study. I am one of the moms whose son has improved on the 6MW since starting on drug. I am also one of the moms who has been meeting with the FDA in an attempt to push them towards rapid approval of eteplirsen, so I guess I have a foot in each camp and a way to observe both closely.
No one in the community is cheering for one drug over another. We all want the fastest possible access to whichever drug works the best, end of story.
The bottom line, from my assessment, which I think is pretty objective at this point, is that Sarepta’s is clearly the superior drug. The company itself is taking a more aggressive path to approval than GSK decided to, which comes with inherent risks and has earned my respect and appreciation. These two facts are the basis behind the support that Jenn Mcnary, Christine McSherry, and I have put behind Sarepta in front of the FDA.